scholarly journals Effect of Low Molecular Weight Fucoidan and Low Molecular Weight Heparin in a Rabbit Model of Arterial Thrombosis

2008 ◽  
Vol 45 (6) ◽  
pp. 529-537 ◽  
Author(s):  
Eric Durand ◽  
Dominique Helley ◽  
Ayman Al Haj Zen ◽  
Céline Dujols ◽  
Patrick Bruneval ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Arterial Thrombosis ◽  
Low Molecular Weight Heparin ◽  
Rabbit Model ◽  
Low Molecular Weight

scholarly journals Validation of the Antifactor Xa and Antifactor IIa Assays for the Potency Assessment of Nadroparin in Pharmaceutical Formulations

2006 ◽  
Vol 89 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Sérgio Luiz Dalmora ◽  
Maximiliano da Silva Sangoi ◽  
Thiago Barth ◽  
Liberato Brum ◽  
Silvana Ferreira Vaccari
Keyword(s):  
Molecular Weight ◽  
Arterial Thrombosis ◽  
Low Molecular Weight Heparin ◽  
Pharmaceutical Formulations ◽  
Pharmaceutical Products ◽  
Low Molecular Weight ◽  
Nadroparin Calcium ◽  
Prevention And Treatment ◽  
Antifactor Xa ◽  
Routine Quality Control

Abstract The low-molecular weight heparin nadroparin calcium is used clinically for the prevention and treatment of venous and arterial thrombosis. The antifactor Xa and antifactor IIa assays were validated by investigating the parameters of range, linearity (r2 0.9905 and r2 0.9914, respectively) precision, accuracy, and robustness. The 2 methods incorporated a chromogenic endpoint and detection at 405 nm, yielding good results with detection limits of 0.004 and 0.01 IU/mL and quantitation limits of 0.01 and 0.03 IU/mL, respectively, for the antifactor Xa and antifactor IIa assays. Nadroparin calcium pharmaceutical products were evaluated by the antifactor Xa assay and the antifactor IIa assay, giving potencies between 93.86 and 109.88%, with an antifactor Xa/antifactor IIa ratio between 3.2 and 3.7. The results demonstrated the validity of the assays that are useful methodologies for the routine quality control of nadroparin in pharmaceutical formulations.

scholarly journals Arterial Mesenteric Thrombosis as a Complication of SARS-CoV-2 Infection

2020 ◽  
Author(s):  
Lia a Beccara ◽  
Carlotta Pacioni ◽  
Sara Ponton ◽  
Simone Francavilla ◽  
Antonio Cuzzoli
Keyword(s):  
Molecular Weight ◽  
Arterial Thrombosis ◽  
Mesenteric Artery ◽  
Low Molecular Weight Heparin ◽  
Symptomatic Patient ◽  
Low Molecular Weight ◽  
Abdominal Ct ◽  
Bowel Distension ◽  
Abdominal Ct Scan ◽  
Mesenteric Thrombosis

A 52-year-old patient with SARS-CoV-2 was diagnosed with interstitial pneumonia and treated with darunavir/ritonavir, hydroxychloroquine, azithromycin and low molecular weight heparin (LMWH). After LMWH cessation, he developed superior mesenteric arterial thrombosis. An abdominal CT scan showed arterial thrombosis of vessels efferent of the superior mesenteric artery with bowel distension. COVID-19 may predispose to venous and arterial thromboembolism. Anticoagulation prophylaxis should be considered in hospitalized patients with COVID-19, and potential thromboembolism investigated in each symptomatic patient affected by SARS-CoV-2.

Prevention of arterial thrombosis in the rabbit by a new low molecular weight heparin (LMWH), BF611

1992 ◽  
Vol 65 ◽  
pp. S155
Author(s):  
C. Bevilacqua ◽  
P. Casotto ◽  
R. Ruhi ◽  
D. Renier ◽  
M. Prosdocimi ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Arterial Thrombosis ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight

A Comparison of the Antithrombotic and Haemorrhagic Effects of a Low Molecular Weight Heparin (LHN-1) and Conventional Heparin

1986 ◽  
Vol 55 (03) ◽  
pp. 410-414 ◽  
Author(s):  
V Diness ◽  
J I Nielsen ◽  
P C Pedersen ◽  
K H Wolffbrandt ◽  
P B Østergaard
Keyword(s):  
Molecular Weight ◽  
Intravenous Administration ◽  
Low Molecular Weight Heparin ◽  
Thrombus Formation ◽  
Rabbit Model ◽  
Endothelial Damage ◽  
Low Molecular Weight ◽  
Dose Ratio ◽  
Experimental Thrombosis ◽  
Antithrombotic Effects

SummaryThe antithrombotic effects after intravenous administration of a low molecular weight heparin (LHN-1) and conventional heparin were compared in a rabbit model of experimental thrombosis, where thrombus formation was induced by a combination of endothelial damage and stasis. Both compounds were able to prevent thrombosis completely. However, LHN-1 was significantly less potent than conventional heparin, the ratio between doses with the same antithrombotic effect being 2.4:1 on a weight basis. Bleeding times after administration of LHN-1 and conventional heparin were determined by tail transsection in anaesthetized rats and by template bleeding in the ear of conscious pigs. Given intravenously at a dose ratio of 2.4:1 (w/w), LHN-1 affected APTT less than conventional heparin, whereas the effects on haemostasis were not significantly different. In conclusion, it was found that after intravenous administration LHN-1 prevented experimental thrombosis as effectively as conventional heparin. However, the correlation between antithrombotic and haemorrhagic effects of LHN-1 was the same as that of conventional heparin. The corresponding relation in man remains to be determined.

Low-molecular-weight heparin in the prevention and treatment of thromboembolic disorders

1998 ◽  
Vol 1 (5) ◽  
pp. 166-174 ◽  
Author(s):  
Evelyn R Hermes De Santis ◽  
Betsy S Laumeister ◽  
Vidhu Bansal ◽  
Vandana Kataria ◽  
Preeti Loomba ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Prevention And Treatment
Sign in / Sign up

Export Citation Format

Share Document